Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2005 2
2006 1
2008 1
2009 1
2010 2
2011 9
2012 8
2013 17
2014 8
2015 15
2016 16
2017 12
2018 7
2019 5
2020 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26815306

101 results

Results by year

Filters applied: . Clear all
Page 1
Protein Z: A putative novel biomarker for early detection of ovarian cancer.
Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, Menon U, Jacobs I, Graham RL. Russell MR, et al. Int J Cancer. 2016 Jun 15;138(12):2984-92. doi: 10.1002/ijc.30020. Epub 2016 Feb 19. Int J Cancer. 2016. PMID: 26815306 Free PMC article.
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV. Karlsen MA, et al. Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24. Gynecol Oncol. 2012. PMID: 22835718 Clinical Trial.
A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I, Graham RLJ. Russell MR, et al. Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29. Br J Cancer. 2017. PMID: 28664912 Free PMC article. Clinical Trial.
Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, Menon U, Bast RC Jr; AOCS Study Group. Yang WL, et al. Clin Cancer Res. 2017 Oct 1;23(19):5912-5922. doi: 10.1158/1078-0432.CCR-17-0284. Epub 2017 Jun 21. Clin Cancer Res. 2017. PMID: 28637689 Free PMC article.
Novel risk models for early detection and screening of ovarian cancer.
Russell MR, D'Amato A, Graham C, Crosbie EJ, Gentry-Maharaj A, Ryan A, Kalsi JK, Fourkala EO, Dive C, Walker M, Whetton AD, Menon U, Jacobs I, Graham RL. Russell MR, et al. Oncotarget. 2017 Jan 3;8(1):785-797. doi: 10.18632/oncotarget.13648. Oncotarget. 2017. PMID: 27903971 Free PMC article.
101 results